Skip to content

Addtional Effect of Hyperbaric Oxygen to Programmed Physical Activity on Musckoloskeletal Pain in Breast Cancer Elderly

Addtion of Hyperbaric Oxygen to Programmed Physical Activity in Aromatse Inhibtors-linked Musckoloskeletal Pain in Breast Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07662629
Enrollment
40
Registered
2026-06-23
Start date
2026-05-07
Completion date
2026-09-01
Last updated
2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

patienst who survived from breast cancer are prescribed long administraion of aromatase inhbitors.. these inhibitors usually induce musckloskeletal pains. Programmed phsyical activity are reommended to improve these pains but effects of HYperbaric oxygen on these pain was not investigated

Detailed description

forty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake were assigned to two groups, group I and group II. the groups received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) but group II additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.

Interventions

OTHERhyperbaric therapy and exercise

Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly fro 2 month) and additinally received one-hour hyperbaric therapy session , five times weekly for 2 month.

OTHERexercise

Twenty elder survivors from breast cancer with musckolskeletal pains resultes from aromatase inhibitor intake received phsyical activity program (aerobci training on traedmill and strengtheining protcol thrice weekly for 2 month).

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
65 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* braest cancer survivors * patients receiving aramatase inhibitor drugs * patients with musckolskeletal pains

Exclusion criteria

* cardiac patients * respiratory patients * renal patients

Design outcomes

Primary

MeasureTime frameDescription
visual analogue scaleit will be measured after 2 monthsit self asessmant of pain level

Secondary

MeasureTime frameDescription
worst painit will be measured after 2 monthsit is a subscore of brief pain inventory
pain severityit will be measured after 2 monthsit is a subscore of brief pain inventory
pain related interferenceit will be measured after 2 monthsit is a subscore of brief pain inventory
pain scoreit will be measured after 2 monthsit is a sub score of Western Ontario and McMaster Universities Osteoarthritis
stifness scoreit will be measured after 2 monthsit is a sub score of Western Ontario and McMaster Universities Osteoarthritis
fucntion scoreit will be measured after 2 monthsit is a sub score of Western Ontario and McMaster Universities Osteoarthritis
total score of Western Ontario and McMaster Universities Osteoarthritisit will be measured after 2 monthsit is usualy used in patients with arthritic pains
Disabilities of the Arm, Shoulder and Hand questionnaireit will be measured after 2 monthsthe short form of it used in patients with arthritic pains
fatigue severity scaleit will be measured after 2 monthsit is used to assess fatigue
Short Physical Performance Batteryit will be measured after 2 monthstotal score used to assess physical performance

Countries

Egypt

Contacts

CONTACTAli MA Ismail, lecturer
ali.mohamed@pt.cu.edu.eg01005154209
CONTACTali moahmed, lecturer
fatmaraed1994@gmail.com01031321109
PRINCIPAL_INVESTIGATORAli MA Ismail, lecturer

Cairo University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 24, 2026